SynAct Pharma AB
Research SynAct Pharma AB (SYNACT) on Bullrun: market cap SEK 996.77M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSYNACT
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 996.77M
- Financial periodQ2 2026
- RevenueSEK 0
- Net income-SEK 22.03M
- Free cash flow-SEK 34.54M
Valuation Snapshot
latest market cap is SEK 996.77M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 110.83M | -SEK 97.33M | n/a | -2.17 | SEK 53.41M | SEK 1.21M | SEK 170.29M |
| FY2024 | SEK 0 | -SEK 82.40M | n/a | n/a | -2.08 | SEK 61.21M | SEK 1.88M | SEK 214.17M |
| FY2023 | SEK 0 | -SEK 215.81M | n/a | n/a | -6.64 | SEK 62.40M | n/a | SEK 176.19M |
| FY2022 | SEK 0 | -SEK 99.21M | n/a | n/a | -3.6 | SEK 108.25M | n/a | SEK 126.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | SEK 996.77M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy.
ETFs that hold SynAct Pharma AB
US-listed ETFs
SynAct Pharma AB is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR Portfolio Europe ETF (SPEU) | <0.01% | 0.07% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SynAct Pharma AB's market cap?
SynAct Pharma AB's market capitalization is SEK 996.77M.
What does SynAct Pharma AB do?
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy.